Government-Owned Inventions; Availability for Licensing, 8213-8214 [2021-02294]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices
Fishers Lane, Room 3G31B, Rockville, MD
20852, (240) 669–5060, james.snyder@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–02274 Filed 2–3–21; 8:45 am]
Government-Owned Inventions;
Availability for Licensing
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–02302 Filed 2–3–21; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Rare Diseases.
Date: February 18, 2021.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1076, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol Lambert, Ph.D.,
Office of Scientific Review, National Center
for Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Boulevard, Room 1076, Bethesda,
MD 20892, 301–435–0814, lambert@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
VerDate Sep<11>2014
17:13 Feb 03, 2021
Jkt 253001
National Institutes of Health
AGENCY:
Dated: January 27, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
jbell on DSKJLSW7X2PROD with NOTICES
Dated: January 22, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Resource Related
Research Projects (R24 Clinical Trial Not
Allowed).
Date: February 23, 2021.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G20,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G20,
Rockville, MD 20852, (240) 669–5068,
zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 26, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02275 Filed 2–3–21; 8:45 am]
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing as a biological material to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Jeffrey Thruston at 301–594–5179 or
jeffrey.thruston@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
National Institutes of Health
BILLING CODE 4140–01–P
8213
A VSV–EBOV-Based Vaccine Against
COVID–19
Description of Technology
Severe acute respiratory syndrome
coronavirus 2 (SARS–CoV–2) is the
causative agent of for coronavirus
disease 2019 (COVID–19). COVID–19 is
characterized by fever, cough, difficulty
breathing, loss of taste and smell,
nausea, and sore throat. As of the fourth
quarter 2020, COVID–19 is responsible
for over 1.17 million deaths worldwide.
As the pandemic continues to surge, the
importance of a safe, affordable, and
efficacious vaccine is of urgent
importance. The present technology
utilizes the well characterized vesicular
stomatitis virus (VSV) encoding the
Ebola virus (VSV–EBOV) to express
additionally a codon-optimized SARS–
CoV–2 spike protein. A single intranasal
or intramuscular administration of the
vaccine showed protective efficacy
against COVID–19 in hamsters after 4
weeks. A single intramuscular injection
showed protective efficacy against
COVID–19 pneumonia in rhesus
macaques within 10 days. The vaccine
is inexpensive to replicate, elicits a high
antigen-specific antibody titer within
E:\FR\FM\04FEN1.SGM
04FEN1
8214
Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices
the host, and provides protective
efficacy after a single dose.
This technology is available for
licensing, as a biological material, for
commercial development in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications
• Single dose vaccine against COVID–
19
Competitive Advantages
• Utilizes the established and well
characterized VSV–EBOV vector
• Expresses high antigen titers within
host cells
• Single dose protective efficacy against
COVID–19
• Inexpensive and replicable
Development Stage
• Prototype
• In vivo/In vitro
Inventors: Andrea Marzi (NIAID),
Wakako Asada (NIAID).
Licensing Contact: To license this
technology, please contact Jeffrey
Thruston at 301–594–5179 or
jeffrey.thruston@nih.gov, and reference
E–233–2017–0.
Dated: January 19, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–02294 Filed 2–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel; NIAID New Innovators
Awards (DP2 Clinical Trial Not Allowed).
VerDate Sep<11>2014
17:13 Feb 03, 2021
Jkt 253001
Date: March 2–3, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Jennifer H. Meyers, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F52, Rockville, MD
20852, 301–761–6602, jennifer.meyers@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 26, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02276 Filed 2–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Library of
Medicine Special Emphasis Panel; K99 and
COI.
Date: March 18, 2021.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Video Assisted Meeting.
Contact Person: Leonid V. Tsap, Ph.D.,
Scientific Review Officer, Extramural
Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 500, Bethesda,
MD 20892–7968, 301–827–7077, tsapl@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Dated: January 26, 2021.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02279 Filed 2–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Human Complex Mental Function
Study Section.
Date: February 24–26, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Karen Elizabeth Seymour,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 240–762–2729, karen.seymour@
nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Acute Neural Injury and Epilepsy
Study Section.
Date: February 25–26, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Paula Elyse Schauwecker,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5201,
Bethesda, MD 20892, 301–760–8207,
schauweckerpe@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Brain Injury
and Neurovascular Pathologies.
Date: February 26, 2021.
Time: 12:00 p.m. to 4:00 p.m.
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 86, Number 22 (Thursday, February 4, 2021)]
[Notices]
[Pages 8213-8214]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02294]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing as a biological material to
achieve expeditious commercialization of results of federally-funded
research and development. Foreign patent applications are filed on
selected inventions to extend market coverage for companies and may
also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Jeffrey Thruston at 301-594-5179 or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
A VSV-EBOV-Based Vaccine Against COVID-19
Description of Technology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
causative agent of for coronavirus disease 2019 (COVID-19). COVID-19 is
characterized by fever, cough, difficulty breathing, loss of taste and
smell, nausea, and sore throat. As of the fourth quarter 2020, COVID-19
is responsible for over 1.17 million deaths worldwide. As the pandemic
continues to surge, the importance of a safe, affordable, and
efficacious vaccine is of urgent importance. The present technology
utilizes the well characterized vesicular stomatitis virus (VSV)
encoding the Ebola virus (VSV-EBOV) to express additionally a codon-
optimized SARS-CoV-2 spike protein. A single intranasal or
intramuscular administration of the vaccine showed protective efficacy
against COVID-19 in hamsters after 4 weeks. A single intramuscular
injection showed protective efficacy against COVID-19 pneumonia in
rhesus macaques within 10 days. The vaccine is inexpensive to
replicate, elicits a high antigen-specific antibody titer within
[[Page 8214]]
the host, and provides protective efficacy after a single dose.
This technology is available for licensing, as a biological
material, for commercial development in accordance with 35 U.S.C. 209
and 37 CFR part 404.
Potential Commercial Applications
Single dose vaccine against COVID-19
Competitive Advantages
Utilizes the established and well characterized VSV-EBOV
vector
Expresses high antigen titers within host cells
Single dose protective efficacy against COVID-19
Inexpensive and replicable
Development Stage
Prototype
In vivo/In vitro
Inventors: Andrea Marzi (NIAID), Wakako Asada (NIAID).
Licensing Contact: To license this technology, please contact
Jeffrey Thruston at 301-594-5179 or [email protected], and
reference E-233-2017-0.
Dated: January 19, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-02294 Filed 2-3-21; 8:45 am]
BILLING CODE 4140-01-P
